Literature DB >> 24553179

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Elisa Rumi1, Ashot S Harutyunyan, Daniela Pietra, Jelena D Milosevic, Ilaria C Casetti, Marta Bellini, Nicole C C Them, Chiara Cavalloni, Virginia V Ferretti, Chiara Milanesi, Tiina Berg, Emanuela Sant'Antonio, Emanuela Boveri, Cristiana Pascutto, Cesare Astori, Robert Kralovics, Mario Cazzola.   

Abstract

Somatic mutations in the calreticulin (CALR) gene were recently discovered in patients with sporadic essential thrombocythemia (ET) and primary myelofibrosis (PMF) lacking JAK2 and MPL mutations. We studied CALR mutation status in familial cases of myeloproliferative neoplasm. In a cohort of 127 patients, CALR indels were identified in 6 of 55 (11%) subjects with ET and in 6 of 20 (30%) with PMF, whereas 52 cases of polycythemia vera had nonmutated CALR. All CALR mutations were somatic, found in granulocytes but not in T lymphocytes. Patients with CALR-mutated ET showed a higher platelet count (P = .017) and a lower cumulative incidence of thrombosis (P = .036) and of disease progression (P = .047) compared with those with JAK2 (V617F). In conclusion, a significant proportion of familial ET and PMF nonmutated for JAK2 carry a somatic mutation of CALR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553179     DOI: 10.1182/blood-2014-01-550434

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Authors:  Ashot S Harutyunyan; Roberto Giambruno; Christian Krendl; Alexey Stukalov; Thorsten Klampfl; Tiina Berg; Doris Chen; Jelena D Milosevic Feenstra; Roland Jäger; Bettina Gisslinger; Heinz Gisslinger; Elisa Rumi; Francesco Passamonti; Daniela Pietra; André C Müller; Katja Parapatics; Florian P Breitwieser; Richard Herrmann; Jacques Colinge; Keiryn L Bennett; Giulio Superti-Furga; Mario Cazzola; Emma Hammond; Robert Kralovics
Journal:  Blood       Date:  2015-11-16       Impact factor: 22.113

Review 2.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 3.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

4.  Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Authors:  Carla Al Assaf; Florence Van Obbergh; Johan Billiet; Els Lierman; Timothy Devos; Carlos Graux; Anne-Sophie Hervent; Jan Emmerechts; Thomas Tousseyn; Pascale De Paepe; Petros Papadopoulos; Lucienne Michaux; Peter Vandenberghe
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

5.  Survival in patients with familial and sporadic myeloproliferative neoplasms.

Authors:  Malin Hultcrantz; Sigrún H Lund; Ola Landgren; Jan Samuelsson; Lynn R Goldin; Asmundur Oddsson; Magnus Björkholm; Sigurdur Y Kristinsson
Journal:  Blood       Date:  2015-06-04       Impact factor: 22.113

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Authors:  Luca Malcovati; Elisa Rumi; Mario Cazzola
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

7.  Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients.

Authors:  Chun Qiao; Chao Sun; Yuan Ouyang; Ju-Juan Wang; Si-Xuan Qian; Jian-Yong Li; Su-Jiang Zhang
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

8.  Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Authors:  X Cabagnols; J P Defour; V Ugo; J C Ianotto; P Mossuz; J Mondet; F Girodon; J H Alexandre; O Mansier; J F Viallard; E Lippert; A Murati; M J Mozziconacci; P Saussoy; M C Vekemans; L Knoops; F Pasquier; V Ribrag; E Solary; I Plo; S N Constantinescu; N Casadevall; W Vainchenker; C Marzac; O Bluteau
Journal:  Leukemia       Date:  2014-09-12       Impact factor: 11.528

Review 9.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

10.  Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.

Authors:  Joseph Saliba; Cécile Saint-Martin; Antonio Di Stefano; Gaëlle Lenglet; Caroline Marty; Boris Keren; Florence Pasquier; Véronique Della Valle; Lise Secardin; Gwendoline Leroy; Emna Mahfoudhi; Sarah Grosjean; Nathalie Droin; M'boyba Diop; Philippe Dessen; Sabine Charrier; Alberta Palazzo; Jane Merlevede; Jean-Côme Meniane; Christine Delaunay-Darivon; Pascal Fuseau; Françoise Isnard; Nicole Casadevall; Eric Solary; Najet Debili; Olivier A Bernard; Hana Raslova; Albert Najman; William Vainchenker; Christine Bellanné-Chantelot; Isabelle Plo
Journal:  Nat Genet       Date:  2015-08-17       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.